Skip to the reading [American Peptide Supply](/) Four chapters on the supply picture - [01 The change](/#the-change) - [02 The history](/#the-history) - [03 Who does what](/#who-does-what) - [04 Keeping care](/#keeping-care) A U.S. supply guide · Updated 27 October 2026 # American Peptide Supply and the week after a shortage 21 February 2025 ## A shortage ends. The week still needs a plan. The FDA [declared the semaglutide injection shortage resolved](https://www.fda.gov/media/185526/download?attachment=), but said local delays could continue. That was a national turning point, even if you were still trying to work out your next prescription. ### Resolved National supply can meet demand. A local delay can still leave you waiting. ![An adult rubs their brow at a kitchen table while a companion rests a hand on their shoulder.](/aps-calendar-3ef9e129bd73/the-week-at-home.webp) ## The week still has to work A shortage announcement can leave plenty to sort out at home. We follow what changed and what it means for the next conversation about care. Despite the name, we don’t sell medicine. American Peptide Supply explains the U.S. shortage story. Here, we follow injection shortages and the compounding rules around them. ## How shortages made room for compounding 2022 · the shortages begin ### The list changes the rules Some semaglutide injection products entered the shortage list in [March 2022 for Wegovy and August for Ozempic](https://www.fda.gov/media/185526/download?attachment=). Tirzepatide injection products were first listed in [December 2022](https://www.fda.gov/media/184606/download?attachment=); the listings did not cover every presentation. Shortage listings [relaxed some limits on compounded copies](https://www.fda.gov/drugs/human-drug-compounding/compounding-when-drugs-are-fdas-drug-shortages-list); other conditions still applied. That gave compounding more room. Compounded drugs are not FDA-approved. ### Compounding Making or changing a medicine for a medical need. Compounded drugs are not FDA-approved. 19 December 2024 · a second decision ### The shortage exception starts to wind down FDA first declared the tirzepatide injection shortage over on 2 October 2024. After a lawsuit prompted another look, its [December decision reached the same conclusion](https://www.fda.gov/media/184606/download?attachment=). Semaglutide’s shortage ended on 21 February 2025. The shortage-based exceptions began to wind down. The shortage alone could no longer justify the same compounding. [See how the dates fit together](/shortage-calendar) ### Enforcement discretion For a set period, FDA said it did not intend to act on certain shortage-related violations. That pause was not drug approval. ## Two sections of law, different jobs ### 503A follows a person Section 503A of the Federal Food, Drug, and Cosmetic Act covers compounding by licensed pharmacists in state-licensed pharmacies or by licensed physicians for an [identified patient with a valid prescription](https://www.fda.gov/media/97347/download). A shortage headline alone can’t explain that person’s needs. ### 503B follows a facility Section 503B covers FDA-registered outsourcing facilities that compound batches of sterile (germ-free) medicines. They can work without individual prescriptions, under [manufacturing rules and FDA inspections](https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities). Their medicines are not FDA-approved. [Untangle 503A and 503B](/503a-and-503b) ## What happens with your next prescription The dates can explain why the rules changed. Your clinician and pharmacist can explain what that means for your care. FDA distinguishes [local delays from national shortages](https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages). For a personal treatment plan, the route is a licensed U.S. clinician who can prescribe, in person or through lawful telehealth. [Make room for the care conversation](/care-continuity) ### Dates, not a live feed Updated 27 October 2026. For today’s national status, the FDA shortage database is the place to check. ## Sources for this reading - [Declaratory Order: Resolution of Shortages of Semaglutide Injection Products](https://www.fda.gov/media/185526/download?attachment=) - [Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products](https://www.fda.gov/media/184606/download?attachment=) - [Compounding when Drugs are on FDA’s Drug Shortages List](https://www.fda.gov/drugs/human-drug-compounding/compounding-when-drugs-are-fdas-drug-shortages-list) - [Prescription Requirement Under Section 503A — full guidance](https://www.fda.gov/media/97347/download) - [Information for Outsourcing Facilities](https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities) - [Frequently Asked Questions about Drug Shortages](https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages) Read on 27 October 2026. [All readings and their context](/references). We follow the supply calendar as a guide; we are neither a clinic nor a pharmacy, and we sell nothing. [References](/references) [About](/about) [Contact](/contact) © 2026 American Peptide Supply